Cargando…

Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction

Background and Objectives: In addition to left ventricular (LV) functions, right ventricular (RV) functions and pulmonary arterial stiffness (PAS) may be adversely affected in patients with heart failure with reduced ejection fraction (HFrEF). Sodium-glucose co-transporter-2 (SGLT2) inhibitor therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Çamcı, Sencer, Yılmaz, Emre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415977/ https://www.ncbi.nlm.nih.gov/pubmed/36013595 http://dx.doi.org/10.3390/medicina58081128

Ejemplares similares

Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction
por: Arslan, Kadem, et al.
Publicado: (2022)

Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension
por: Patel, Ravi B., et al.
Publicado: (2020)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022)

Right Ventricular Dimension for Heart Failure With Preserved Ejection Fraction Involving Right Ventricular-Vascular Uncoupling
por: Nakagawa, Akito, et al.
Publicado: (2022)

Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction
por: Schmeißer, Alexander, et al.
Publicado: (2021)

Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022)

Prognostic Implications of Changes in Left Ventricular Ejection Fraction and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction
por: Kim, Hyun-Jin
Publicado: (2019)

Correlation Between Liver Stiffness and Diastolic Function, Left Ventricular Hypertrophy, and Right Cardiac Function in Patients With Ejection Fraction Preserved Heart Failure
por: Zhang, Junyi, et al.
Publicado: (2021)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
por: Chi, Chen, et al.
Publicado: (2021)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients
por: Kwon, Hee-Jin, et al.
Publicado: (2019)

Impact of Diabetes Mellitus on Ventricular Structure, Arterial Stiffness, and Pulsatile Hemodynamics in Heart Failure With Preserved Ejection Fraction
por: Chirinos, Julio A., et al.
Publicado: (2019)

Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance
por: Goliasch, Georg, et al.
Publicado: (2015)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Relationship between Pulmonary Artery Stiffness and Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction
por: Yildirim, Erkan, et al.
Publicado: (2017)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Increased Left Ventricular Stiffness Impairs Exercise Capacity in Patients with Heart Failure Symptoms Despite Normal Left Ventricular Ejection Fraction
por: Sinning, David, et al.
Publicado: (2011)

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction
por: Nonin, Shinichi, et al.
Publicado: (2018)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2020)

Assessment of right ventricular systolic function in heart failure with preserved, reduced and mid-range ejection fraction
por: Mostafa, Shaimaa
Publicado: (2019)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Forgotten No More—The Role of Right Ventricular Dysfunction in Heart Failure with Reduced Ejection Fraction: An Echocardiographic Perspective
por: Vijiiac, Aura, et al.
Publicado: (2021)

Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Pressure‐based estimation of right ventricular ejection fraction
por: Heerdt, Paul M., et al.
Publicado: (2022)

Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction
por: Parasuraman, Sathish K., et al.
Publicado: (2019)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
por: Wang, Yintang, et al.
Publicado: (2022)

Impact of Sex on Ventricular‐Vascular Stiffness and Long‐Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy
por: Beale, Anna L., et al.
Publicado: (2019)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2022)

Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction
por: Ali, Danish, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gkc1bjotps6s8b544cdbc27o7q